NCT00319449View on ClinicalTrials.gov

Adding Ezetimibe Tablet to Ongoing Treatment With Atorvastatin in Subjects With High Cholesterol and Multiple Coronary Heart Disease Risk Factors (Study P04060)(COMPLETED)

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

October 31, 2006

Study Completion Date

October 31, 2006

Conditions

HypercholesterolemiaCoronary Arteriosclerosis

Interventions

DRUG

Ezetimibe

10 mg ezetimibe, orally, daily for 6 weeks, added to ongoing treatment with 10 mg atorvastatin

DRUG

Placebo

10 mg/day matching placebo to ezetimibe, orally, daily for 6 weeks, added to ongoing 10 mg atorvastatin

DRUG

Atorvastatin 10 mg

10 mg/day atorvastatin, orally, (ongoing treatment in participants)

All Listed Sponsors

collaborator

PT. Schering-Plough. Tbk Indonesia

UNKNOWN

lead

Organon and Co

INDUSTRY

NCT00319449 - Adding Ezetimibe Tablet to Ongoing Treatment With Atorvastatin in Subjects With High Cholesterol and Multiple Coronary Heart Disease Risk Factors (Study P04060)(COMPLETED) | Biotech Hunter | Biotech Hunter